Ketotifen Unit Dose Stulln

Ketotifen, the active ingredient in Ketotifen Unit Dose Stulln, is an antihistamine (H1 receptor antagonist and mast cell stabilizer) presented as a unit‑dose ophthalmic solution for topical ocular use. It is indicated for the relief of allergic conjunctivitis and other allergic eye conditions in patients of all ages.

GNH USA supplies Ketotifen Unit Dose Stulln as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑sourced manufacturing network and ensuring compliance with global quality standards.

Ketotifen is used to manage ocular allergic conditions by blocking histamine‑mediated inflammation. - Allergic conjunctivitis: reduces redness, itching and watery discharge. - Seasonal allergic eye disease: alleviates symptoms triggered by pollen or other seasonal allergens. - Itchy eyes due to allergic reactions: provides rapid relief of itching and discomfort.

Ketotifen ophthalmic solution may cause local or systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Burning sensation: mild eye irritation that usually resolves within minutes after instillation. - Stinging or itching: temporary discomfort that diminishes shortly after dosing. - Blurred vision: transient visual disturbance that clears without intervention.

Serious or Rare Side Effects: - Allergic contact dermatitis: local hypersensitivity reaction presenting as redness, swelling, and itching of the eyelid skin. - Corneal ulceration: rare but severe corneal damage that may cause pain, discharge, and requires urgent ophthalmic care. - Vision loss: extremely rare, sudden decrease in visual acuity that mandates immediate medical evaluation.

When using Ketotifen ophthalmic solution, several precautions should be observed to ensure safety and efficacy. - Contraindication: avoid use in patients with known hypersensitivity to ketotifen or any formulation components. - Contact lens use: remove contact lenses before instillation and wait at least 15 minutes before reinserting. - Pregnancy: safety has not been established; use only if potential benefit outweighs risk. - Breastfeeding: limited data; consider potential exposure to infant and consult healthcare provider. - Systemic disease: caution in patients with severe asthma or other mast‑cell disorders, as systemic absorption may occur. - Store at ambient temperature: keep below 25°C, protect from light and moisture in the original container.

Ketotifen may interact with other ophthalmic or systemic agents; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticholinergic eye drops: may increase ocular dryness when combined. - MAO inhibitors: potential for enhanced antihistaminic effects leading to systemic sedation (though rare with topical use).

Moderate Interactions (Monitor Closely): - Other antihistamine eye drops: additive effect may increase risk of irritation. - Systemic antihistamines: may potentiate sedation or anticholinergic side effects. - Topical corticosteroids: concurrent use may mask signs of infection.